Coya Therapeutics (COYA) vs Medicinova (MNOV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Medicinova (MNOV) has outperformed Coya Therapeutics (COYA) over the past year, losing 8.4% versus a loss of 50.7%. Coya Therapeutics is the larger company by market cap ($69.2 million vs $67.1 million), about 1.0 times the size. Coya Therapeutics converts more of its revenue into profit, with a net margin of -267.1% versus -2928.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COYA | MNOV |
|---|---|---|
| Share price | $2.95 | $1.31 |
| Market cap | $69.20M | $67.11M |
| 1-day change | -1.01% | +3.15% |
| YTD return | -49.14% | 0.00% |
| 1-year return | -50.67% | -8.39% |
| 5-year return | — | -59.32% |
| EPS (TTM) | $-1.39 | $-0.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $7.95M | $409.66K |
| Revenue growth (YoY) | +123.57% | — |
| Net income (latest FY) | $-21.23M | $-12.00M |
| Operating margin | -283.87% | -3242.47% |
| Net margin | -267.14% | -2928.78% |
| 52-week high | $6.62 | $3.90 |
| 52-week low | $2.72 | $1.22 |
| Distance from 52-week high | -55.44% | -66.41% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +415.59% | +529.77% |
| Average volume | 149.18K | 334.96K |
| Shares outstanding | 23.46M | 51.23M |
| Employees | 8 | 6 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MNOV has outperformed COYA by 42.3 percentage points over the past year.
- Coya Therapeutics is more profitable, keeping -267.1 cents of every revenue dollar as net income versus -2928.8 cents for Medicinova.
About Coya Therapeutics
COYA stock →Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
About Medicinova
MNOV stock →MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
COYA vs MNOV FAQ
Which is bigger, Coya Therapeutics or Medicinova?
Coya Therapeutics (COYA) is larger, with a market capitalization of $69.20M compared with $67.11M for Medicinova (MNOV).
Which stock has performed better over the past year, COYA or MNOV?
MNOV returned -8.39% over the past 12 months, compared with -50.67% for COYA (price return, excluding dividends). Past performance does not predict future results.
Are Coya Therapeutics and Medicinova in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.